SCHEMBL643844

SCHEMBL643844

COC(=O)c1ccccc1N(C)S(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.59
GAA P10253 2/20 0.56
NPSR1 Q6W5P4 1/20 0.56
ALPL P05186 1/20 0.55
ALPI P09923 1/20 0.55
ALPG P10696 1/20 0.55
ALDH1A1 P00352 3/20 0.52
TSHR P16473 1/20 0.52
MAPT P10636 2/20 0.51
HTT P42858 1/20 0.51
POLB P06746 2/20 0.48
RAB9A P51151 1/20 0.48
KDM4E B2RXH2 2/20 0.47
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MCOLN3 Q8TDD5 1/20 0.46
MEN1 O00255 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577031 0.89 KMT2A (0.55) KMT2AGAANPSR1ALPLALPI
SCHEMBL645509 0.86 TDP1 (0.58) KMT2AGAAALPLALPIALPG
SCHEMBL25221412 0.83 GAA (0.76) KMT2AGAANPSR1ALDH1A1MAPT
SCHEMBL644106 0.80 KMT2A (0.48) KMT2AGAAALPLALPIALPG
SCHEMBL14033827 0.78 KMT2A (0.46) KMT2AGAAALPLALPIALPG
SCHEMBL14033453 0.78 KMT2A (0.46) KMT2AGAAALPLALPIALPG
SCHEMBL7683091 0.76 GAA (0.57) KMT2AGAANPSR1ALDH1A1MAPT
SCHEMBL647372 0.75 KMT2A (1.00) KMT2AGAANPSR1ALDH1A1TSHR
SCHEMBL645178 0.75 KMT2A (0.46) KMT2AALPLALPIALPGALDH1A1
SCHEMBL493681 0.75 KMT2A (0.50) KMT2AALPLALPIALPGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119633-B2 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases GRUENENTHAL GMBH (DE) 2012-02-21 US disclosed
EP-2150530-B1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2011-10-26 EP disclosed
EP-2150530-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-02-10 EP disclosed
US-20080312231-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
WO-2008131947-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312231-A1 Substituted Sulfonamide Compounds SULT2A1, SULT1A1, SCN1A KMT2A 2577/4885GAA 260/4885NPSR1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.